This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Weiss, L., Reich, S., and Slavin, S. Use of recombinant human interleukin 2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2 activated cell-mediated immunotherapy. Cancer Investigation, 10, 19–26 (1992).
Abella, A., Messaoudi, C., Laurent, D., Marot, D., Chalas, J., Breux, J., Claise, C., and Lindenbaum, A. A method for simulataneous determination of plasma and erythrocyte antioxidant status. Evaluation of the antioxidant activity of vitamin E in healthy volunteers. BrJ Clin. Pharmacol, 42, 737–741 (1996).
Chevion, S., Berry, E.M., Ktrowssky, N., and Kohen, R. Evaluation of plasma low molecular weight antioxidants by voltametry. Free Rad. Biol. Med., 22, 411–471 (1997).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Nir, I., Weiss, L., Slavin, S. (2002). The Use of Melatonin and Cotreatment with Autologous or Allogeneic Cells as a Model for Control of Malignant β-cell Leukemia. In: Olcese, J. (eds) Melatonin After Four Decades. Advances in Experimental Medicine and Biology, vol 460. Springer, Boston, MA. https://doi.org/10.1007/0-306-46814-X_48
Download citation
DOI: https://doi.org/10.1007/0-306-46814-X_48
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46134-7
Online ISBN: 978-0-306-46814-8
eBook Packages: Springer Book Archive